Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert J. Hombach is Director at BioMarin Pharmaceutical. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jun 4, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
2
Robert J. Hombach has no open-market purchase on record since 2013. Sales in 1 of the 14 years since 2013.
Robert J. Hombach reported 0 open-market purchases and 1 sale since 2013; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2013 | — | $3.51M1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Jun 2, 20267,490disclosed Jun 4
DetailsOfficial recordHenry ScheinHSIC
Mar 6, 20262,577disclosed Mar 9
DetailsOfficial recordAs of the latest filing on , Robert J. Hombach reported holding 49,360 shares of BioMarin Pharmaceutical (BMRN), worth about $3.03M at the last close of $61 (Nov 19, 2026). Holdings are also on file at Henry Schein (HSIC); together they are worth about $3.49M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical BMRN | 49,360 | 49K direct | $61 | $3.03M | Jun 2, 2026 |
| Henry Schein HSIC | 5,421 | 5,421 direct | $85 | $460K | Mar 6, 2026 |
Is this Robert J. Hombach’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Jun 2, 2026, Robert J. Hombach reported holding 49,360 shares of BioMarin Pharmaceutical (BMRN). At the last close of $61 on Nov 19, 2026, that is about $3.03M. This is the stake disclosed in filings, not a net worth.
No public filing gives Robert J. Hombach's net worth. What SEC Form 4 shows is the stock stake: 49,360 shares of BioMarin Pharmaceutical (BMRN), about $3.03M at the last close, plus holdings in 1 other company, about $3.49M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Robert J. Hombach has no open-market purchase on record since 2013. Sales in 1 of the 14 years since 2013.
In SEC filings since 2013: no open-market purchase is on record; the latest open-market sale is from 2013.
Baxter International (BAX), from 2013 to 2013: 0 purchases and 1 sale.
Robert J. Hombach reported 0 open-market purchases and 1 sale here, 2013.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.